Compare Davita Inc (DVA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Snowflake Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Snowflake Inc trades at $331.84 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 9.9× Davita Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SNOW | |
|---|---|---|
Market Cap | $11.72B | $116.01B |
Sector | Health | Technology |
52-Week High | $240.96 | $334.70 |
52-Week Low | $103.87 | $121.11 |
Enterprise Value | $24.44B | $115.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Snowflake (SNOW) trades at $330.49, up 3.93% in 24 hours, approaching its 52-week high. The stock exhibits bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue growth is robust at $3.63 billion in 2025, but net losses persist at -$1.29 billion. Recent news highlights AI-driven partnerships and product launches, such as Spotfire's integration with Snowflake AI Data Cloud (Business Wire, 2026-08-05).
The outlook remains optimistic due to strong analyst buy ratings (80.77%) and a consensus price target of $302.18, though high valuation multiples (P/S 22.37) and ongoing losses pose risks. Key opportunities include AI expansion and customer growth, while competition and margin pressure are concerns. Investors should weigh growth potential against profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
